Pediatric Praziquantel Consortium

Executive from Merck KGaA, Darmstadt, Germany re-emphasises the importance of addressing the treatment gap of preschoolers infected with schistosomiasis

22 June 2018

Initiation of the Phase III development program by the Pediatric Praziquantel Consortium announced at the WHA...

Renowned African Research Institutes Join Pediatric Praziquantel Consortium

22 May 2018

Complementary experience offered by the Kenya Medical Research Institute (KEMRI) and the Université Félix Houphouët-...

A story of schistosomiasis infection in Ghana

A story of schistosomiasis infection in Ghana.
Video credit: Shelly Xie

Vision

Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more

Mission

Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

Soon after its formation, the consortium established a pediatric drug development program, divided into two major steps: preclinical development, and clinical development.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. This formulation that aims to use small, orally dispersible tablets with an acceptable taste. 

Read more